StoneApp: Effectiveness of WhatsApp Education and Support Messages for Urolithiasis Prevention

Sponsor
Rabin Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05627622
Collaborator
(none)
200
1
2
83
2.4

Study Details

Study Description

Brief Summary

Kidney and ureteral stones are a common problem in primary care practice with increasing prevalence over the last few decades.

Prevention of recurrent stones (which are usually composed primarily of calcium oxalate) is aimed at decreasing the concentrations of the lithogenic factors. There are several metabolic and dietary treatable components. In all patients with urolithiasis, adequate fluid intake and lower body mass index are key components to reducing the risk of recurrent stones. For most patients, additional beneficial dietary modifications are increasing intake of fruits and vegetables which are rich in potassium, and reducing intake of candies and sweetened juices which are rich in sucrose and fructose. In addition, for patients who have been prescribed medications, adherence to medication may become an important issue over the long term.

Mobile technology has the potential to optimize health care and patient's adherence, especially through personal education and dissemination of health information. One of the most common technologies available on mobile is the WhatsApp Messenger® application. WhatsApp is a freeware messaging service; it allows streamlining patient-provider communication via text and voice messages, video clips and images.

The research hypotheses are, first, that use of WhatsApp to disseminate information regarding stones preventive measures will have a substantial positive effect on follow-up compliance and on patient's adherence to the preventive measures. Second, we expect reduction in cumulative stone recurrence rate.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: WhatsApp health education message
N/A

Detailed Description

Kidney and ureteral stones are a common problem in primary care practice with increasing prevalence over the last few decades. Nineteen percent of men and nine percent of women will be diagnosed with a kidney stone by the age of 70 years,and the rates of emergency department visit for urolithiasis were increased from 178 to 340 visits per 100,000 individuals from 1992 to 2009 (United States).

Prevention of recurrent stones, which are usually composed primarily of calcium oxalate, is aimed at decreasing the concentrations of the lithogenic factors. There are several metabolic and dietary treatable components. In all patients with urolithiasis, adequate fluid intake and lower body mass index are key components to reducing the risk of recurrent stones. For most patients, additional beneficial dietary modifications are increasing intake of fruits and vegetables which are rich in potassium, and reducing intake of candies and sweetened juices which are rich in sucrose and fructose. In addition, for patients who have been prescribed medications, adherence to medication may become an important issue over the long term.

As early as the 1980s, "The stone clinic effect" on the recurrence rate of stone disease was published. Hosking et al. demonstrated that a regimen of increased fluid intake and appropriate dietary modifications, to avoid dietary excesses, reduces stone growth and new stone formation in patients with idiopathic calcium urolithiasis.

According to the 2019 European Association of Urology guidelines on urolithiasis, all stone formers, independent of their individual risk, should follow preventive measures such as circadian fluid drinking of 2.5-3 liter daily, limitation of NaCl content to 5 gram daily.

The trials documenting benefit from these preventive measures required at least three years before the results were significant. However, in an analysis of over 3000 patients followed in a well-organized stone clinic at the University of Chicago, between 20% and 30% of patients were lost to follow-up every year. Only 15 to 40 percent of patients complied with the follow-up requirements by three years. Adherence to long-term therapy among those who did not follow-up was presumably very low. Hence, improving patient's adherence and follow-up compliance is of paramount importance.

Mobile technology has the potential to optimize health care and patient's adherence, especially through personal education and dissemination of health information. One of the most common technologies available on mobile is the WhatsApp Messenger® application. WhatsApp is a freeware messaging service; it allows streamlining patient-provider communication via text and voice messages, video clips and images.

The research hypotheses are, first, that use of WhatsApp to disseminate information regarding stones preventive measures will have a substantial positive effect on follow-up compliance and on patient's adherence to the preventive measures. Second, we expect reduction in cumulative stone recurrence rate.

Methods Hypotheses will be tested in a randomized control trial. Participants will be recruited at the stone clinic of Rabin Medical Center, an academic tertiary hospital. Participants will randomly assign to one of two groups: A, the experimental group, receiving stone-prevention information on a monthly basis, and B, the control group.

Statistical Analysis Based on recurrence rates of previous studies the required number of patients was calculated in expectation of 20% and 40% cumulative recurrence rate of renal stones at 5 years in the experimental and control group, respectively. Type 1 error was set to 5%, and type 2 error was set to 20%. With this assumption, each group has to include 81 patients. Risk and rate ratio of stone recurrence and 95% confidence intervals (CIs) will be calculated. Loss of patients from follow-up will be measured by proportion of patients lost at each year.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control trialRandomized control trial
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effectiveness of WhatsApp Education and Support Messages for Urolithiasis Prevention
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2027
Anticipated Study Completion Date :
Dec 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group,

Receiving stone-prevention information on a monthly basis, using WhatsApp Messenger® application.

Behavioral: WhatsApp health education message
stone-prevention information on a monthly basis, using personal WhatsApp messages

No Intervention: control group

will not receive stone-prevention information

Outcome Measures

Primary Outcome Measures

  1. stone recurrence [5 years]

    urinary stone recurrence

Secondary Outcome Measures

  1. mean time to relapse [5 years]

    mean time to urinary stone event

  2. lost to follow-up rate [5 years]

    lost to "urinary stone clinic" follow-up rate

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Capacity to give informed consent

  • Personal history of urolithiasis

  • Stone free status

  • A personal mobile phone with WhatsApp Messenger® application

Exclusion Criteria:
  • Children

  • Does not read Hebrew, the language in which the messages are written

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rabin Medical Center Petah Tikva Israel 49414

Sponsors and Collaborators

  • Rabin Medical Center

Investigators

  • Principal Investigator: MIchael Frumer, MD, Rabin Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michael Frumer, Dr., Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT05627622
Other Study ID Numbers:
  • StoneApp
First Posted:
Nov 25, 2022
Last Update Posted:
Nov 25, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Michael Frumer, Dr., Rabin Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 25, 2022